Acquisition will help Predictive Biosciences launch cancer-management diagnostics.
Predictive Biosciences acquired OncoDiagnostic Laboratory (ODL), a private CLIA-certified anatomic pathology and molecular diagnostics lab. It provides Predictive with a fully integrated pathology laboratory through which the company will commercialize its noninvasive molecular cancer tests.
The first in Predictive’s portfolio of high-performance assays for improved cancer management is a urine-based biomarker test for the detection of bladder cancer. The company expects commercialization during this year.
ODL serves urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians nationwide. “ODL’s subspecialty expertise and national access to hundreds of urology practices including some of the largest group practices in the U.S. such as the Conrad|Pearson Clinic in Tennessee and the Arizona Urology Specialists favorably position Predictive for launching our bladder cancer test as well as future diagnostic products,” notes Peter Klemm, Ph.D., president and CEO for Predictive.
“In light of ODL’s established national sales presence, its accomplished team of pathologists, history of innovation, and consistent high marks for quality and customer service, we could not imagine a better, more mission-aligned partner to proceed with,” Dr. Klemm continues. “We look forward to leveraging ODL’s urology focused sales organization to introduce our proprietary bladder cancer assay later this year.”
ODL, which was founded in 1985 by a group of pathologists to better serve the growing needs of office-based urologists and other subspecialty physicians, will continue to operate from its Cleveland, OH, headquarters. ODL currently employs approximately 40 professionals including a national sales force that is supported by company pathologists, laboratory staff, and customer service.
